Allogene Therapeutics develops genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, pioneering "off-the-shelf" products derived from healthy donors that can be administered to any patient without individualized manufacturing. The company uses proprietary gene-editing technology and in-house manufacturing to engineer T cells that minimize rejection risk while promoting durability, offering potential advantages in cost, availability, and consistency compared to autologous cell therapies. Revenue will be generated through standard pharmaceutical distribution upon regulatory approval and reimbursement, with commercial success dependent on clinical trial outcomes, manufacturing scale, and market adoption in competitive oncology and emerging autoimmune disease segments.